| Gene Symbol |
ACKR3
|
| Entrez Gene |
57007
|
| Alt Symbol |
CMKOR1, CXC-R7, CXCR-7, CXCR7, GPR159, RDC-1, RDC1
|
| Species |
Human
|
| Gene Type |
protein-coding
|
| Description |
atypical chemokine receptor 3
|
| Other Description |
C-X-C chemokine receptor type 7|G protein-coupled receptor|G-protein coupled receptor 159|G-protein coupled receptor RDC1 homolog|chemokine (C-X-C motif) receptor 7|chemokine orphan receptor 1
|
| Swissprots |
Q92986 A8K6J4 Q8NE10 P25106 Q92938 Q53RV4
|
| Accessions |
AAB18130 AAX93086 CCE67098 CCE67101 EAW71092 P25106 AF030297 AAB94130 AK291659 BAF84348 BC008459 BC036661 AAH36661 BM925428 BP426139 DB455412 DQ822477 ABH01258 DQ891241 ABM82167 DQ894426 ABM85352 M64749 AAA62370 U67784 AAB16913 XM_005246097 XP_005246154 XM_005246098 XP_005246155 XM_011511503 XP_011509805 NM_020311 NP_064707 NM_001047841
|
| Function |
Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. Chemokine binding does not activate G-protein- mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization and activation of MAPK signaling pathway. Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness. In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Promotes cell growth and survival. Not involved in cell migration, adhesion or proliferation of normal hematopoietic progenitors but activated by CXCL1
|
| Subcellular Location |
Cell membrane; Multi-pass membrane protein. Cytoplasm, perinuclear region. Early endosome. Recycling endosome {ECO:0000250}. Note=Predominantly localizes to endocytic vesicles, and upon stimulation by the ligand is internalized via clathrin- coated pits in a beta-arrestin-dependent manner. Once internalized, the ligand dissociates from the receptor, and is targeted to degradation while the receptor is recycled back to the cell membrane.
|
| Tissue Specificity |
Expressed in monocytes, basophils, B-cells, umbilical vein endothelial cells (HUVEC) and B-lymphoblastoid cells. Lower expression detected in CD4+ T-lymphocytes and natural killer cells. In the brain, detected in endothelial cells and capillaries, and in mature neurons of the frontal cortex and hippocampus. Expressed in tubular formation in the kidney. Highly expressed in astroglial tumor endothelial, microglial and glioma cells. Expressed at low levels in normal CD34+ progenitor cells, but at very high levels in several myeloid malignant cell lines. Expressed in breast carcinomas but not in normal breast tissue (at protein level). {ECO:0000269|PubMed:16107333, ECO:0000269|PubMed:16455976, ECO:0000269|PubMed:19641136, ECO:0000269|PubMed:20388803, ECO:0000269|PubMed:20887389, ECO:0000269|PubMed:21655198}.
|
| Top Pathways |
Cytokine-cytokine receptor interaction
|